IQVIA Holdings Inc. $IQV Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 46.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,065 shares of the medical research company’s stock after purchasing an additional 24,236 shares during the period. Natixis Advisors LLC’s holdings in IQVIA were worth $17,146,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $27,000. Westside Investment Management Inc. boosted its stake in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $30,000. Finally, Activest Wealth Management boosted its stake in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Morgan Stanley set a $225.00 target price on IQVIA in a research note on Thursday, May 7th. UBS Group reduced their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $224.13.

IQVIA Stock Performance

Shares of IQV opened at $183.56 on Friday. The business’s fifty day moving average price is $172.12 and its 200 day moving average price is $194.94. IQVIA Holdings Inc. has a 12-month low of $147.62 and a 12-month high of $247.04. The stock has a market capitalization of $30.64 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 1.60 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business posted $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.